Browsing St. Olavs hospital by Author "Aksnessæther, Bjørg Yksnøy"
Now showing items 1-5 of 5
-
Detection of recurrent prostate cancer with 18F-Fluciclovine PET/MRI
Selnæs, Kirsten Margrete; Krüger-Stokke, Brage; Elschot, Mattijs; Johansen, Håkon; Steen, Per Arvid; Langørgen, Sverre; Aksnessæther, Bjørg Yksnøy; Indrebø, Gunnar; Sjøbakk, Torill Eidhammer; Tessem, May-Britt; Moestue, Siver Andreas; Knobel, Heidi; Tandstad, Torgrim; Bertilsson, Helena; Solberg, Arne; Bathen, Tone Frost (Peer reviewed; Journal article, 2020)Objective: Simultaneous PET/MRI combines soft-tissue contrast of MRI with high molecular sensitivity of PET in one session. The aim of this prospective study was to evaluate detection rates of recurrent prostate cancer by ... -
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P)
Löffeler, Sven; Bertilsson, Helena Maria; Müller, Christoph Rainer; Aas, Kirsti; Haugnes, Hege Sagstuen; Aksnessæther, Bjørg Yksnøy; Pesonen, Maiju; Thon, Kristian; Tandstad, Torgrim; Murtola, Teemu; Poulsen, Mads Hvid Aaberg; Nordstrøm, Tobias; Vigmostad, Maria Nyre; Ottosson, Fredrik; Holmsten, Karin; Christiansen, Ola B.; Slaaen, Marit; Haug, Erik Skaaheim; Storås, Anne Holck; Asphaug, Lars; Rannikko, Antti; Brasso, Klaus (Peer reviewed; Journal article, 2024)Background Older men (aged ≥75 years) with high risk, non-metastatic prostate cancer (PCa) are increasingly treated with curative therapy (surgery or radiotherapy). However, it is unclear if curative therapy prolongs ... -
Radiotherapy for prostate cancer – Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial
Tøndel, Hanne; Lund, Jo-Åsmund; Lydersen, Stian; Wanderås, Anne Dybdahl; Aksnessæther, Bjørg Yksnøy; Jensen, Christer André; Kaasa, Stein; Solberg, Arne (Journal article; Peer reviewed, 2018)Background Novel cancer drugs are subject to strict scientific evaluation of safety and efficacy and usually undergo a cost effectiveness analysis before approval for use in clinical practice. For new techniques in ... -
Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial
Aksnessæther, Bjørg Yksnøy; Myklebust, Tor Åge; Solberg, Arne; Klepp, Olbjørn; Skovlund, Eva; Hoff, Solveig Roth; Fosså, Sophie Dorothea; Widmark, Anders; Lund, Jo-Åsmund (Peer reviewed; Journal article, 2019)Background Curative radiation therapy (RT) constitutes a cornerstone in prostate cancer (PC) treatment. We present long-term follow-up estimates for second cancer (SC) risk and overall survival (OS) in patients randomized ... -
Second cancers in radically treated Norwegian prostate cancer patients
Aksnessæther, Bjørg Yksnøy; Lund, Jo-Åsmund; Myklebust, Tor Åge; Klepp, Olbjørn; Skovlund, Eva; Hoff, Solveig Roth; Solberg, Arne (Journal article; Peer reviewed, 2019)Introduction: The aim of this registry-based cohort study was to estimate second cancer (SC) risk following radical prostate cancer (PC) treatment and evaluate if the risk was influenced by radiotherapy. Materials and ...